MedTrace Logo

Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer

NCT03702868 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 226

Last updated 2021-01-29

No results posted yet for this study

Summary

Breast cancer is the most common cause of cancer death in women. Adjuvant chemotherapy significantly reduces the risk of recurrence of high-risk breast cancer. However, about 30% of patients still have distant metastasis or local recurrence after chemotherapy. Moreover, 60% of patients had 3-4 degrees of adverse drug reactions during chemotherapy.

The purpose of the study is to investigate relationship between gut microbiome and adjuvant chemotherapy in early breast cancer patients.

Conditions

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Zhong-yu Yuan, M.D. · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2020-10-30
Completion
2020-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03702868 on ClinicalTrials.gov